FindTrial
Sign In

Dendritic Cell Therapy

BIOLOGICAL3 trials

Sponsors

Universitair Ziekenhuis Brussel, Mayo Clinic, Jonsson Comprehensive Cancer Center

Conditions

Aggressive Non-Hodgkin LymphomaDiffuse Hemispheric Glioma, H3 G34-MutantIndolent Non-Hodgkin LymphomaMalignant Melanoma Stage IIIMalignant Melanoma Stage IVRecurrent Diffuse Large B-Cell LymphomaRecurrent Follicular LymphomaRecurrent Mantle Cell Lymphoma

Phase 1

Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma
CompletedNCT03035331
Mayo ClinicAggressive Non-Hodgkin Lymphoma, Indolent Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma +7
Start: 2017-08-15End: 2022-09-10Updated: 2025-05-16
A Vaccine (Neoantigen-Targeted ppDC) for the Treatment of H3 G34-mutant Diffuse Hemispheric Glioma
Active, not recruitingNCT06342908
Jonsson Comprehensive Cancer CenterDiffuse Hemispheric Glioma, H3 G34-Mutant
Start: 2024-06-14End: 2028-01-09Target: 6Updated: 2026-02-17

Phase 2

mRNA Electroporated Autologous Dendritic Cells for Stage III/IV Melanoma
CompletedNCT01676779
Universitair Ziekenhuis BrusselMalignant Melanoma Stage III, Malignant Melanoma Stage IV
Start: 2012-10-31End: 2016-09-30Target: 88Updated: 2017-05-24